March 22, 2022
Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
– VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection that could broaden…